Quantcast

Latest Osteonecrosis of the jaw Stories

2011-02-25 08:41:28

By: Rhonda Craig, Ivanhoe Health Correspondent (Ivanhoe Newswire)  -- An osteoporosis drug designed to improve bone health may be associated with femoral fractures. Bisphosphonates are a group of prescription medications used to treat bone loss in osteoporosis patients. But in this new study, researchers found that older women who used these medications for a longer period of time were more likely to experience atypical fractures. "We found that women who are 68 years or older, who take...

2011-02-24 18:05:00

THOUSAND OAKS, Calif., Feb. 24, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced the publication of results from a Phase 3 head-to-head trial that compared XGEVA(TM) (denosumab) to Zometa(®) (zoledronic acid) in preventing bone complications called skeletal-related events (SREs) in 1,901 men with prostate cancer and bone metastases. The study, published in The Lancet, met its primary and secondary endpoints and demonstrated XGEVA's superiority compared to Zometa...

2011-02-23 12:56:52

However, the drugs do prevent hip fractures Women who take commonly prescribed drugs for osteoporosis known as bisphosphonates for five years or more may be at higher risk of certain kinds of fractures of their thigh bone, a new study has found. However, the drugs do prevent hip fractures. And, since the overall risk of thigh bone fractures caused by the drugs is low, women at high risk for hip and other osteoporosis-related fractures should not stop taking bisphosphonates, according to...

2011-02-23 01:50:42

Older women who used bisphosphonates (medications that prevent loss of bone mass) for five years or more were more likely to experience "atypical" fractures involving the femoral shaft (bone in the leg that extends from the hip to the knee) or subtrochanteric (fractures in the bone just below the hip joint), compared to women with less usage. However, the absolute risk of these "atypical" fractures was low and bisphosphonate use was associated with a reduced risk of typical osteoporotic...

2011-02-22 15:05:00

THOUSAND OAKS, Calif., Feb. 22, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced the publication of results from a pivotal Phase 3 study of 1,776 advanced cancer patients with different types of solid tumors (not including breast and prostate cancer) or multiple myeloma, which compared XGEVA(TM) (denosumab) to Zometa® (zoledronic acid) in preventing skeletal-related events (SREs). The study, which appeared today in the Journal of Clinical Oncology, found that...

2011-02-14 15:54:40

A commonly prescribed osteoporosis drug is associated with a slightly elevated risk of developing the rare, but serious condition, osteonecrosis of the jaw; nonetheless the risk remains extremely low. These findings are published online in the Journal of Dental Research, the official journal of the International and American Associations for Dental Research. Although the findings are provocative, study authors say they should be carefully considered against the large benefit of these drugs to...

2011-02-14 10:29:00

CHICAGO, Feb. 14, 2011 /PRNewswire/ -- Zoledronic acid (sold by Novartis as Zometa, Aclasta, and Reclast) is used to treat Osteoporosis, Tumor Metastasis, and Paget's Disease with sales of $2 billion a year.(1) It is associated with side effects such as post-dose syndrome and osteonecrosis of the jaw. A new patented method from Dr. Ketan Desai enables the administration of Zoledronic acid in combination with another drug that relieves the side effects. (Logo:...

2011-02-11 21:25:22

Results may have an important impact to the developing of better definitions for ONJ Osteonecrosis of the jaw (ONJ) is a debilitating bone condition that affects the jaws and occurs as a result of reduced local blood supply to the bone. The literature in this area has been severely limited since most investigations cannot evaluate sufficient numbers of afflicted individuals to accurately determine the incidence of the disease and associated risk factors. Today, the International and American...

2010-12-13 16:52:00

THOUSAND OAKS, Calif., Dec. 13, 3010 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced top-line results from a Phase 3 trial evaluating XGEVA(TM) (denosumab) versus placebo in 1,432 men with castrate-resistant prostate cancer. The trial, known as the '147 study, demonstrated that XGEVA significantly improved median bone metastasis-free survival by 4.2 months (HR=0.85, 95 percent CI 0.73-0.98, p=0.03) compared to placebo (primary endpoint), and significantly improved time to...

2010-12-10 15:34:00

THOUSAND OAKS, Calif., Dec. 10, 2010 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced results from new analyses comparing XGEVA(TM) (denosumab), the first new treatment for advanced cancer patients with bone metastases in nearly a decade to prevent skeletal-related events, to Zometa® (zoledronic acid). These results underscore the efficacy profile of XGEVA in preventing skeletal-related events (SREs) in patients with bone metastases from advanced breast...


Word of the Day
siliqua
  • A Roman unit of weight, 1⁄1728 of a pound.
  • A weight of four grains used in weighing gold and precious stones; a carat.
  • In anatomy, a formation suggesting a husk or pod.
  • The lowest unit in the Roman coinage, the twenty-fourth part of a solidus.
  • A coin of base silver of the Gothic and Lombard kings of Italy.
'Siliqua' comes from a Latin word meaning 'a pod.'
Related